| Philip | A few months <a href=" http://accesstocompletion.com/zyprexa-online.pdf#executive ">zyprexa relprevv</a> For 2013, the company now expects core earnings of $4.72 to $5.12 per share and revenue of $2.274 to $2.34 billion. It earlier expected earnings of 5.76 to $6.26 per share and revenue of $2.37 to $2.48 billion. Analysts expect earnings of $5.91 per share on revenue of $2.38 billion. |
|